High-functioning mild-to-borderline intellectual disorders (MBID) and autism spectrum disorder (ASD) constitute leading global public health challenges due to their high prevalence, chronicity, and profound cognitive and functional impact. The interplay between neuronutrition, physical activity, and mental health for enhancing brain resilience to stress and overall human health is widely recognized. The use of brain mapping via quantitative-EEG (qEEG) comparative analysis enables researchers to identify deviations or abnormalities and track the changes in neurological patterns when a targeted drug or specific nutrition is administered over time.
Objective: The objectives of the present study were twofold: first, to characterize an extremely vulnerable group of children with functioning autism symptoms, disclosing their overall pattern of cognitive abilities and areas of difficulty, and second, to investigate the relevance of the effects of a mushroom (Hericium erinaceus) biomass dietary supplement on improvement on neurocognitive behavior.
Methods: This study used qEEG to compare raw data with a normative database to track the changes in neurological brain patterns in 147 children with high-functioning autistic attributes when mushroom H. erinaceus biomass supplement was consumed over 6 and 12 months.
Conclusions: H. erinaceus biomass in children with pervasive developmental disorders significantly improved the maturation of the CNS after 6 to 12 months of oral use, decreased the dominant slow-wave activity, and converted slow-wave activity to optimal beta1 frequency. Despite limited number of observations, it may be concluded that the H. erinaceus biomass may generate a complex effect on the deficits of the autism spectrum when applied to high-functioning MBID children, representing a safe and effective adjunctive strategy for supporting neurodevelopment in children.
Nutrients 2026 Jan 13;18(2):248. doi: 10.3390/nu18020248
The Hericium erinaceus biomass used in this study was supplied by Mycology Research Laboratories Ltd and MLD Trading.
Clinical Articles
The following section outlines the clinical papers, posters and proposals that refer to the clinical use of MRL mushroom nutrition products. This information is for healthcare practitioners only and should not be provided to members of the general public.
Download PDF
Clinical articles
-
Neuroprotective Effects of Mushroom Biomass Digestive Fractions and Gut Microbiota Metabolites in Microglial and Caenorhabditis elegans Models of Neurodegeneration
Helena Araújo-Rodrigues 1,2 , Lidia Garzón-García 3 Freni K. Tavaria 1 , Celestino Santos-Buelga 3 , Ana Sofia Salsinha 1 , João Bettencourt Relvas 2,4 , Ana M.González-Paramás 3 and Manuela E.Pintado1,* -
Bioaccessibility and Bioavailability of Bioactive Compounds from Mushroom Biomass Following in vitro Gastrointestinal Digestion presented at the CIPCA 2025 X International Conference on Food Proteins and Collides June 16-18, 2025 in Porto Portugal.
Helena Araújo-Rodrigues, Manuela Machado, João B. Relvas , Freni K. Tavaria, Manuela Pintado -
Neuroprotective Effects of Mushroom Biomass: Impact of Serum-Available and Gut Microbiota Metabolites in Caenorhabditis elegans Models of Alzheimer’s Disease. Presented on June 13th at the XXIII EURO FOODCHEM 2025 Conference in Bratislava, Slovakia
Helena Araújo-Rodrigues,Lidia Garzón-García, João B. Relvas, Freni K. Tavaria, Celestino Santos-Buelga, Ana M. González-Paramás, and Manuela E. Pintado -
Chemical Composition of Trametes versicolor, Hericium erinaceus, and Pleurotus ostreatus Mushroom Biomass: Deciphering their Rich α-glucan Composition and Nutritional Value
Helena Araújo-Rodrigues, Manuela Amorim, Clara Sousa, Ana Sofia Salsinha, Sara Marçal, Victor de Freitas, Joao Bettencourt Relvas, Freni K. Tavaria,Manuela E. Pintado. Journal of Food Composition and Analysis 143 (2025) 107612.